Study to evaluate the safety and tolerability of <i>Streptococcus salivarius</i> eK12, a genetically modified strain derived from the oral probiotic S. <i>salivarius</i> K12: Results from a randomized, double-blind, placebo-controlled, parallel-group clinical trial.

Front Nutr · 2025 · PMC12719284 · PMID 41438195

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

A two-tailed p -value of < 0.05 was considered nominally significant.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Study to evaluate the safety and tolerability of &lt;i&gt;Streptococcus salivarius&lt;/i&gt; eK12, a genetically modified strain derived from the oral probiotic S. &lt;i&gt;salivarius&lt;/i&gt; K12: Results from a randomized, double-blind, placebo-controlled, parallel-group clinical trial.

The sentences

Study to evaluate the safety and tolerability of <i>Streptococcus salivarius</i> eK12, a genetically modified strain derived from the oral probiotic S. <i>salivarius</i> K12: Results from a randomized, double-blind, placebo-controlled, parallel-group clinical trial.